PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo

Pfizer Inc. (PFE) announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease. Following the latest FDA nod, Abrysvo has become the first and only RSV vaccine approved for adults who are younger than 50 years. Abrysvo is currently approved for t ...